Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable last year at $19.9 million, even as the vaccines company navigated a “challenging regulatory and business environment.” ...
Investor's Business Daily on MSN
Moderna pops as Vinay Prasad, the FDA's controversial vaccine head, will depart in April
Moderna stock jumped late Friday on reports the FDA's top vaccine official, Vinay Prasad, will step down amid mounting ...
COVID-19 vaccine recommendations could be changing, according to the U.S. Food and Drug Administration. FDA leaders said on May 20 that clinical trials will be required to approve annual COVID-19 ...
The Food and Drug Administration’s vaccine chief, Dr. Vinay Prasad, will depart the agency next month, an FDA spokesperson ...
Boomi, the data activation company, today announced it has been recognised as a Leader and positioned highest for Ability to ...
The approval represents a win in what’s been a difficult regulatory environment of late for vaccine makers, and could boost ...
Researchers developed DoriVac, a DNA origami-based vaccine platform that precisely arranges antigens and adjuvants to enhance ...
Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading today, for the April 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA options ...
The ECDC, the infectious diseases watchdog, has asked for scientists to join its new panel on RSV as Europe begins to vaccinate its most vulnerable adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results